| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3979323 | Bulletin du Cancer | 2011 | 12 Pages |
Abstract
Targeted therapies used (angiogenesis inhibitors and mTOR inhibitors) in advanced renal cell carcinoma have a constellation of reaction affecting the skin, hair and nails. This guideline describes the incidence, clinical presentation and treatment of dermatologic side effects that develop with the use of targeted therapies (sunitinib, sorafenib, pazopanib, bevacizumab, everolimus, temsirolimus).
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Caroline Robert, Pierre Gimel,